Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

MEK inhibitor I × Dermatologic × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 3 Tumor-Agnostic 1 Gastrointestinal 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 303 Nivolumab 268 Ipilimumab 241 Cyclophosphamide 179 aldesleukin 137 Interleukin-2 98 fludarabine phosphate 96 trametinib 79 fludarabine 77 Temozolomide 73 Dacarbazine 73 Radiotherapy 70 dabrafenib 69 Biopsy 68 Vemurafenib 64 Imiquimod 49 Radiosurgery 48 Bevacizumab 48 Magnetic Resonance Spectroscopy 46 Blood Specimen Collection 46 sargramostim 44 Aminolevulinic Acid 44 3-ingenyl angelate 44 Specimen Handling 43 Peripheral Blood Stem Cell Transplantation 43 Cisplatin 42 Paclitaxel 41 binimetinib 40 atezolizumab 39 Carboplatin 39

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02382549 2023-12-12

Mel61

University of Virginia

Phase EARLY_PHASE1 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡